Lenzetto® safety and tolerability information
In a study of 454 women who received Lenzetto®,
application site reactions appeared in just 1.3% of women1
Common reported adverse events (≥1/100 to <1/10)2
- Headache
- Abdominal pain
- Nausea
- Rash
- Pruritus
- Breast pain
- Breast tenderness
- Uterine/Vaginal bleeding including spotting
- Metrorrhagia
- Weight increase or decrease
Reasons for immediate withdrawal of therapy2
- Jaundice or deterioration in liver function
- Significant increase in blood pressure
- New onset of migraine-type headache
- Pregnancy
Contraindications2
- Known, past or suspected breast cancer
- Previous or current venous thromboembolism
- Acute liver disease, or a history or liver disease as long as liver function tests have failed to return to normal
- Known or suspected oestrogen-dependent malignant tumours
- Known thrombophilic disorders
- Porphyria
- Undiagnosed genital bleeding
- Active or recent arterial thromboembolic disease
- Hypersensitivity to estradiol, ethanol or octisalate
- Untreated endometrial hyperplasia
For the complete listing of precautions, risks and the adverse event profile, please consult the link to the Summary of Product Characteristics at the bottom of this page.Lenzetto does not contain any ingredients derived from an animal source.